샘플 요청 목록

 카트 문의
시장보고서
상품코드
1768750

세계의 차세대 시퀀싱(NGS) 데이터 분석 시장

Next Generation Sequencing (NGS) Data Analysis
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 437 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 차세대 시퀀싱 데이터 분석 시장은 2030년까지 23억 달러에 이를 전망

2024년에 10억 달러로 추정되는 차세대 시퀀싱(NGS) 데이터 분석 세계 시장은 2024-2030년 CAGR 13.9%로 성장하여 2030년에는 23억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 서비스는 CAGR14.7%를 나타내고, 분석 기간 종료시에는 14억 달러에 이를 것으로 예측됩니다. NGS 상용 소프트웨어 부문의 성장률은 분석 기간중 CAGR 12.7%로 추정됩니다.

미국 시장은 3억 6,530만 달러로 추정, 중국은 CAGR 15.2%로 성장 예측

미국의 차세대 시퀀싱 데이터 분석 시장은 2024년에 3억 6,530만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 2억 2,920만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 15.2%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 12.9%와 13.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 13.6%를 나타낼 전망입니다.

세계의 차세대 시퀀싱 데이터 분석 시장 - 주요 동향과 촉진요인 정리

차세대 시퀀싱 데이터 분석이란 무엇이며, 왜 혁명적인가?

차세대 시퀀싱 데이터 분석은 차세대 시퀀싱 기술로 생성되는 방대한 양의 데이터를 해석하는 과정을 말하며, NGS는 기존에 사용되던 싱거 시퀀싱보다 훨씬 빠르고 저렴하게 DNA와 RNA를 시퀀싱할 수 있으며, 방대한 양의 데이터를 생성합니다. 생성합니다. 이러한 데이터를 분석하기 위해서는 데이터 처리, 정렬, 조립, 주석을 다루는 생물정보학 도구와 소프트웨어가 필요하며, 원시 염기서열 데이터를 이해할 수 있는 유전 정보로 변환합니다. 이 정보는 유전체학, 종양학, 약리유전체학, 복잡한 질병 연구 등 다양한 과학적 응용에 매우 중요합니다. 높은 처리량, 확장성, 초고속 시퀀싱을 제공하는 NGS의 능력으로 인해 NGS는 현대 유전자 연구의 초석이 되어 생물학적 시스템에 대한 이해를 변화시키고 있습니다.

기술의 발전은 차세대 시퀀싱 데이터 분석을 어떻게 형성하고 있는가?

차세대 염기서열 데이터 분석 분야는 바이오인포매틱스, 클라우드 컴퓨팅, 인공지능의 끊임없는 발전으로 큰 혜택을 받고 있습니다. 바이오인포매틱스는 보다 빠르고 정확한 분석을 가능하게 하는 정교한 알고리즘과 소프트웨어를 통해 데이터의 복잡성과 크기를 관리하기 위해 발전해 왔습니다. 클라우드 컴퓨팅은 방대한 데이터 세트를 원격으로 저장하고 처리할 수 있게 함으로써 전 세계 연구자들에게 확장성과 접근성을 제공함으로써 데이터 분석에 혁명을 일으켰습니다. 또한, AI와 머신러닝은 유전자의 변이와 기능을 이해하는 데 중요한 패턴 인식을 자동화함으로써 유전자 데이터 분석의 효율성을 향상시키는 데 매우 중요한 역할을 하고 있습니다. 이러한 기술은 질병 감수성 및 약물 반응을 예측하는 능력을 향상시켜 개인 맞춤형 의료로 가는 길을 열어줄 것입니다.

차세대 시퀀싱 데이터 분석의 주요 과제와 기회는 무엇인가?

이러한 발전에도 불구하고, 차세대 시퀀싱 데이터 분석은 큰 문제에 직면해 있습니다. 주요 장애물 중 하나는 생성되는 방대한 양의 데이터 관리이며, 이를 효과적으로 처리하기 위해서는 상당한 연산 능력과 강력한 데이터 관리 시스템이 필요합니다. 또한, 데이터 분석의 복잡성으로 인해 정확한 분석을 위해서는 고도의 기술을 가진 생물정보학자와 유전학자가 필요합니다. 또한, 복잡한 유전자 구조에 대한 종합적인 통찰력을 제공하기 위해 NGS 데이터를 다른 유형의 생물학적 데이터와 통합해야 하는 과제도 있습니다. 그러나 이러한 도전은 계산생물학 분야의 혁신을 촉진하고, 차세대 시퀀싱 데이터 분석의 속도, 정확성, 비용 효율성을 지속적으로 개선하는 보다 정교한 분석 도구와 방법론의 개발로 이어지고 있습니다.

차세대 시퀀싱 데이터 분석 시장의 성장을 가속하는 요인은?

차세대 시퀀싱 데이터 분석 시장의 성장은 기술적, 경제적, 사회적 변화를 반영하는 몇 가지 요인에 의해 이루어지고 있습니다. 시퀀싱 기술의 기술적 발전으로 유전자 시퀀싱의 처리량 향상과 비용 절감으로 의학 연구, 임상 진단, 개인 맞춤형 의료 등 다양한 분야에서 NGS에 대한 접근성이 확대되고 있습니다. 빅데이터 분석과 강화된 컴퓨팅 성능의 통합으로 보다 빠르고 정교한 데이터 분석이 가능해져 빠른 결과에 대한 수요 증가에 대응하고 있습니다. 경제적으로는 세계 생명공학 및 제약 부문의 확장이 유전체학 및 NGS에 대한 투자를 촉진하고 시장 성장을 더욱 촉진하고 있습니다. 사회적으로는 일반 대중과 의료 서비스 제공업체 사이에서 유전체 의학에 대한 인식과 수용이 증가하고 있으며, 이는 정밀의료를 장려하는 정부 이니셔티브에 의해 뒷받침되고 있습니다.

부문

컴포넌트(서비스, NGS 상용 소프트웨어), 워크플로우(3차 데이터 분석, 1차 데이터 분석, 2차 데이터 분석), 모드(인 하우스, 아웃소싱), 최종사용자(학술 연구, 임상 연구, 병원 및 클리닉, 제약 기업 및 바이오테크놀러지 기업, 기타 최종사용자)

조사 대상 기업 예

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • AB Sciex LLC
  • Asuragen, Inc.
  • Adaptive Biotechnologies Corporation
  • BGI-Shenzhen
  • Beijing Novogene Bioinformatics Technology Co., Ltd.
  • ABL(Advanced Biological Laboratories) SA
  • Admera Health
  • Arima Genomics
  • 1010Genome
  • Basepair
  • BGI Genomics

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH 25.07.18

Global Next Generation Sequencing (NGS) Data Analysis Market to Reach US$2.3 Billion by 2030

The global market for Next Generation Sequencing (NGS) Data Analysis estimated at US$1.0 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 13.9% over the analysis period 2024-2030. Services, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Ngs Commercial Software segment is estimated at 12.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$365.3 Million While China is Forecast to Grow at 15.2% CAGR

The Next Generation Sequencing (NGS) Data Analysis market in the U.S. is estimated at US$365.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$229.2 Million by the year 2030 trailing a CAGR of 15.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 13.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.6% CAGR.

Global Next Generation Sequencing (NGS) Data Analysis Market - Key Trends & Drivers Summarized

What Is Next Generation Sequencing (NGS) Data Analysis, and Why Is It Revolutionary?

Next Generation Sequencing (NGS) data analysis refers to the process of interpreting the vast amounts of data produced by next generation sequencing technologies. NGS allows for the sequencing of DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing, and it generates massive volumes of data. The analysis of these data involves bioinformatics tools and software that handle data processing, alignment, assembly, and annotation to translate raw sequencing data into understandable genetic information. This information is crucial for a broad range of scientific applications, including genomics, oncology, pharmacogenomics, and complex disease studies. The ability of NGS to provide high-throughput, scalable, and ultra-fast sequencing makes it a cornerstone in modern genetic research, transforming our understanding of biological systems.

How Are Technological Advancements Shaping NGS Data Analysis?

The field of NGS data analysis has greatly benefited from continual advancements in bioinformatics, cloud computing, and artificial intelligence. Bioinformatics has evolved to manage the complexity and size of data through sophisticated algorithms and software that can deliver faster and more accurate analysis. Cloud computing has revolutionized data analysis by enabling the storage and processing of enormous datasets remotely, providing scalability and accessibility to researchers around the world. Furthermore, AI and machine learning have begun to play pivotal roles in improving the efficiency of genetic data analysis by automating pattern recognition, which is crucial for understanding genetic variations and functions. These technologies enhance the ability to predict disease susceptibility and drug responses, paving the way for personalized medicine.

What Are the Major Challenges and Opportunities in NGS Data Analysis?

Despite its advancements, NGS data analysis faces significant challenges that also present opportunities for growth and improvement. One of the primary hurdles is the management of the sheer volume of data generated, which requires substantial computational power and robust data management systems to handle effectively. Additionally, the complexity of data interpretation demands highly skilled bioinformaticians and geneticists to ensure accurate analyses. There is also the challenge of integrating NGS data with other types of biological data to provide comprehensive insights into complex genetic structures. However, these challenges drive innovation in computational biology, leading to the development of more sophisticated analysis tools and methodologies that continually improve the speed, accuracy, and cost-effectiveness of NGS data analysis.

What Factors Are Propelling the Growth of the NGS Data Analysis Market?

Growth in the NGS data analysis market is driven by several factors that reflect technological, economic, and social shifts. Technological advances in sequencing technologies continue to increase the throughput and reduce the cost of genetic sequencing, expanding the accessibility of NGS for various applications in medical research, clinical diagnostics, and personalized medicine. The integration of big data analytics and enhanced computational power allows for more sophisticated and quicker data analysis, catering to the growing demand for rapid results. Economically, the expansion of biotechnology and pharmaceutical sectors worldwide fuels investment in genomics and NGS, further promoting market growth. Socially, there is a rising awareness and acceptance of genomic medicine among the public and healthcare providers, which is supported by government initiatives promoting precision medicine.

SCOPE OF STUDY:

The report analyzes the Next Generation Sequencing (NGS) Data Analysis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Services, NGS Commercial Software); Workflow (Tertiary Data Analysis, Primary Data Analysis, Secondary Data Analysis); Mode (In-House, Outsourced); End-Use (Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 111 Featured) -

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • AB Sciex LLC
  • Asuragen, Inc.
  • Adaptive Biotechnologies Corporation
  • BGI-Shenzhen
  • Beijing Novogene Bioinformatics Technology Co., Ltd.
  • ABL (Advanced Biological Laboratories) SA
  • Admera Health
  • Arima Genomics
  • 1010Genome
  • Basepair
  • BGI Genomics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Next Generation Sequencing (NGS) Data Analysis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • NGS Data Analysis: Unraveling Critical Clues to Solve Scientific Problems
    • NGS Data Analysis: Insights into File Formats & Downstream Analysis
    • File Formats for NGS Raw Data
    • NGS Data: Downstream Analysis
    • Global Market Overview and Prospects
    • Next-Generation Sequencing (NGS) Data Analysis Market Witnesses Burgeoning Growth
    • Key Market Drivers and Inhibitors
    • Market Analysis
    • US and Europe Lead, Asia-Pacific to Witness Growth
    • Analysis by Product
    • Analysis by Workflow
    • Analysis by Mode
    • Analysis by Read Length
    • Analysis by End-Use
    • Competitive Landscape
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Next Generation Sequencing Market Drives the Demand for NGS Data Analysis
    • Increasing R&D Activities in NGS
    • Rising Use of NGS in Drug Discovery Drives Growth of NGS Data Analysis
    • Rising Application of Whole Genome Sequencing Drives Demand for Faster Secondary Analysis Tools
    • Technological Advancements in Sequencing Techniques and Data Integration
    • Research Initiatives for the Development of NGS-based In-vitro Diagnostics
    • The Need for Large-scale NGS Data Analysis Pushes for Cloud-enabled Bioinformatics Services
    • NGS Data Analysis Using Big Data Gains Ground
    • Improving Regulatory & Reimbursement Scenario for NGS-based Diagnostic Tests
    • Increase in Genome Mapping Programs
    • Declining Costs of Genome Sequencing Drive Market Growth
    • Growth of Long-Read Sequencing to Propel the Market for NGS Data Analysis
    • Aging Demographics Present Opportunities
    • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Growing Prevalence of Chronic Diseases to Boost the Market Prospects
    • Rising Diabetes Prevalence: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Market Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ngs Commercial Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Ngs Commercial Software by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Tertiary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Tertiary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Primary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Primary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Secondary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Secondary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for In-House by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Outsourced by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Outsourced by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World 6-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 27: World Next Generation Sequencing (NGS) Data Analysis Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • JAPAN
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • CHINA
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 52: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • EUROPE
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • FRANCE
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 70: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • GERMANY
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • UNITED KINGDOM
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 94: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: UK 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of World 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제